CHMP Nod Little Consolation As Amgen's Imlygic Becomes Melanoma Also-Ran
This article was originally published in Scrip
Amgen's oncolytic virus therapy Imlygic (talimogene laherparepvec) has been given a positive opinion in advanced melanoma by Europe's top scientific advisory panel, but significant changes in the competitive landscape mean the drug is unlikely to garner high sales.
You may also be interested in...
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis and Pfizer are helping to fund a public-private partnership aimed at improving the primary care health infrastructure in Africa; the collaboration will also exploit the companies’ experience providing therapies and using digital and web-enabled technologies.
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.